Additionally, SLMP53-1 inhibited glycolysis, with downregulation of several glycolytic intervenient, including glucose transporters (GLUT1) and enzymes (HK2 and PFKFB3), which are direct p53 targets, in cancer cells and xenograft tumor tissue. This evidence concerns the gene TP53 and cancer.